In oncology, Maball is used alone or in combination with other cytotoxic anticancer agents to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia. In rheumatology and autoimmune care, it is combined with methotrexate for moderate-to-severe rheumatoid arthritis in patients who haven't responded adequately to other disease-modifying therapies, and is also used for granulomatosis with polyangiitis, microscopic polyangiitis (both inflammatory blood vessel conditions affecting lungs and kidneys), and pemphigus vulgaris, a severe autoimmune blistering skin condition. It is suitable for use in adults and, for certain indications, in children aged 6 months and older.
The injection is administered exclusively via intravenous infusion under close medical supervision — never as an IV push or bolus — with premedication given before each infusion to reduce the risk of infusion reactions. The first infusion typically starts at a slow rate, gradually increased if well tolerated. Patients are monitored for infusion-related reactions, which can occur during or within 24 hours of administration and, in rare cases, can be severe. Since Rituximab suppresses the immune system, patients are also monitored for infection risk, including possible reactivation of hepatitis B.